BASE-LINE CLINICAL AND ANGIOGRAPHIC DATA IN THE QUINAPRIL ISCHEMIC EVENT (QUIET) TRIAL

The QUinapril Ischemic Event Trial (QUIET) is the first prospective, d ouble-blind, placebo-controlled trial to investigate the long-term ant iatherosclerotic effects of angiotensin-converting enzyme inhibition. Normotensive, nonhyperlipidemic subjects (1,750) with normal left vent ricular systolic function were randomly assigned to treatment or place bo at percutaneous transluminal coronary angioplasty (PTCA). The prima ry end point is time to first cardiac ischemic event. Baseline clinica l characteristics are (mean +/- SD): age 58 +/- 9 years; blood pressur e 123 +/- 15/74 +/- 10 mm Hg; low density lipoprotein cholesterol 124 +/- 27 mg/dL; high density lipoprotein cholesterol 37 +/- 10 mg/dl; an d triglycerides 167 +/- 91 mg/dL. In addition, 81% are men; 22% are cu rrent smokers; 49% give a history of myocardial infarction. Baseline a ngiographic characteristics are (mean +/- SD):left ventricular ejectio n fraction 59% +/- 11%; per patient diameter stenosis (excluding the P TCA segment) 49% +/- 31%; 8.9 +/- 3.5 analyzable segments per patient (excluding the PTCA segment), 3.8 +/- 2.3 of which have visible stenos is. Including the PTCA segment, 52% have single vessel disease and 48% have multivessel disease. Baseline angiographic data for non-PTCA seg ments will be correlated with cardiac ischemic: events which occur aft er 6 months. Up to 500 subjects will undergo followup angiography with quantitative coronary angiographic analysis (QCA) of baseline and fol low-vp films. The primary QCA end point will be per-patient categorica l designation as progressor or nonprogressor based on the presence or absence of greater than or equal to 400 mu m narrowing in greater than or equal to 1 vessels that did not undergo PTCA. (C) 1996 by Excerpta Medica, Inc.